Factors associated with improved DpR in the final multiple regression model were panitumumab treatment (vs. FOLFOX4 alone), liver-only metastatic disease (vs. liver + other or other only), WT BRAF status (vs. mutant) and an ECOG performance status of 0 or 1 (vs. 2) (Table 2a). The gene discussed is BRAF; the disease is metastatic neoplasm.